Sleep Apnea Common in Pulmonary Hypertension, Study Finds
A recent study highlights the importance of treating pulmonary hypertension in patients with obstructive sleep apnea.
Tag: PAH and pulmonary hypertension
All
Latest
All
Latest
Pulmonary Hypertension Patients Exhibited Reduced Exercise Capacity Under Hypoxia
Results of a clinical trial show that patients with pulmonary hypertension (PH) have a lower capacity for exercise during hypoxia.
All
Latest
Very Few Pulmonary Hypertension Patients Given Pulmonary Rehabilitation
Among 111,356 veterans with pulmonary hypertension, only 1,737 (1.6%) patients received pulmonary rehabilitation.
Pulmonary Arterial Hypertension Treatment With Macitentan Is Safe and Effective for Patients With Systemic Sclerosis
Patients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read More
Pulmonary Arterial Hypertension Patients Benefit from Macitentan + Tadalafil Combo
Patients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read More
No Benefit for Idiopathic Interstitial Pneumonia-associated PH Patients Treated with Adempas
For patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read MoreSelexipag Functionally Improves Pulmonary Hypertension Patients with COPD
Selexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.In trial data presented at...
Read MoreNew Drug Target Discovered for the Lung Disease PAH
Scientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension (PAH), a severe, often fatal condition that has no cure. The discovery, published Sept. 12, 2019,...
Read More
Pulmonary Arterial Hypertension Device Receives FDA Breakthrough Designation
SoniVie has been granted breakthrough device designation from the US FDA for their device to treat patients with pulmonary arterial hypertension (PAH).
Read More
Tumor-suppressing Protein May Be Novel Target in PAH Therapy
In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).
Read More
Selexipag Improved Clinical Outcomes in Pulmonary Arterial Hypertension
Treatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.
Read More
Pulmonary Arterial Hypertension Tied to Protein Production
Development of pulmonary arterial hypertension (PAH) may be related to increased production of Nestin protein in the pulmonary vasculature, a Plos One study reports.
Read More
Positive Data for PAH Patients Treated with Riociguat
According to results from the MOTION study, improvements were seen across several patient-reported outcomes for patients with pulmonary arterial hypertension (PAH) treated with Riociguat (Adempas).
Read More
RT Awareness and Preferences Regarding Pulmonary Hypertension Treatment
RTs may find it difficult to choose between available inhaled pulmonary vasodilators (IPVs)—inhaled nitric oxide or nebulized epoprostenol—to treat pulmonary hypertension.
Read More
Bayer Enrolling Patients in Phase 4 PAH Trial of Riociguat
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH).
Read More